APx Acquisition Corp. I
APXIW
NASDAQ Global Select0.06
USD
+0.01
- -
APx Acquisition Corp. I
APXIW
(NASDAQ Global Select)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- APx Acquisition Corp. I APx Acquisition Corp. I operates as a blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities; it focuses primarily on opportunities in Spanish-speaking Latin American countries or companies outside Latin America that provide goods and services to Spanish-speaking markets, including technology-enabled firms. Incorporated in 2021 and headquartered in Nashville, Tennessee, at 714 Westview Avenue, the company completed a $172.5 million initial public offering in December 2021, with Class A ordinary shares and warrants trading under the symbols APXI and APXIW, respectively, on Nasdaq prior to the delisting of warrants and units in late 2024 due to failing to meet minimum market value requirements. APx Acquisition Corp. I maintains no significant ongoing operations or products beyond its capital pool held in trust, which supports due diligence and negotiation for a target business combination; it employs a small team of two, led by Chairman and CEO Kyle P. Bransfield, a serial SPAC sponsor, in partnership with Daniel Braatz and Xavier Martinez of APx Capital. In March 2024, the company entered a definitive business combination agreement valued at approximately $340 million with OmnigenicsAI Corp., a precision medicine firm incubated by Bioceres Group PLC offering DNA and microbiome testing for prevention, RNA screening for early disease detection, and specialized genetic diagnostics in oncology, prenatal care, rare diseases, and human microbiome complemented by telemedicine; the deal also initially included MultiplAI Health Ltd., a UK-based AI-enabled preventive medicine company, but terminated that portion in August 2024 due to regulatory risks and operational discrepancies while proceeding with OmnigenicsAI. More recently, shareholders extended the business combination deadline to December 9, 2025; the company issued promissory notes totaling $1.146 million at 20% interest to Bioceres LLC, an indirect OmnigenicsAI shareholder, to fund ongoing efforts; faced Nasdaq delisting notifications for its Class A shares in December 2024 for failing to complete a combination within 36 months of IPO, prompting a planned transition to OTC markets without impacting the OmnigenicsAI pursuit; and as of mid-2025 filings, continues pursuing the merger with regulatory submissions like Form F-4 ongoing.